Italian study tracks how long CLL patients stay on acalabrutinib in daily practice

NCT ID NCT06205498

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 151 Italian adults with chronic lymphocytic leukemia (CLL) who started taking acalabrutinib between May 2021 and April 2022. Researchers want to see how long patients continue the drug and why they might stop, providing real-world insights beyond clinical trials. The study does not test a new treatment but observes existing use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib (Calquence), a targeted drug for chronic lymphocytic leukemia
What this could lead to: If successful, this study could confirm that acalabrutinib works well in everyday practice, helping doctors make better treatment decisions for CLL patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient differences. It only looks at treatment duration, not overall survival or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Show contact details

Locations

Research Site

Alessandria, 15121, Italy
Research Site

Ancona, 60126, Italy
Research Site

Bari, 70124, Italy
Research Site

Barletta, 76121, Italy
Research Site

Brindisi, 72100, Italy
Research Site

Campobasso, 86100, Italy
Research Site

Catania, 95100, Italy
Research Site

Catanzaro, 88100, Italy
Research Site

Cosenza, 87100, Italy
Research Site

Crema, 26013, Italy
Research Site

Cuneo, 12100, Italy
Research Site

Foggia, 71122, Italy
Research Site

Frosinone, 03100, Italy
Research Site

Genova, 16132, Italy
Research Site

Lecce, 73100, Italy
Research Site

Messina, 98158, Italy
Research Site

Milan, 20122, Italy
Research Site

Milan, 20132, Italy
Research Site

Monza, 20900, Italy
Research Site

Naples, 80131, Italy
Research Site

Padova, 35128, Italy
Research Site

Pagani, 84016, Italy
Research Site

Perugia, 06132, Italy
Research Site

Pescara, 65124, Italy
Research Site

Ravenna, 48121, Italy
Research Site

Reggio Calabria, 89133, Italy
Research Site

Roma, 00133, Italy
Research Site

Roma, 00161, Italy
Research Site

Roma, 00168, Italy
Research Site

Roma, 00184, Italy
Research Site

Roma, 00189, Italy
Research Site

Rozzano, 20089, Italy
Research Site

Salerno, 84078, Italy
Research Site

San Giovanni Rotondo, 71013, Italy
Research Site

Torino, 10043, Italy
Research Site

Torino, 10073, Italy
Research Site

Torino, 10126, Italy
Research Site

Torino, 10154, Italy
Research Site

Tricase, 73039, Italy
Research Site

Varese, 21100, Italy
Research Site

Viterbo, 01100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.